BR112019004314A2 - derivados pró-insulina - Google Patents

derivados pró-insulina

Info

Publication number
BR112019004314A2
BR112019004314A2 BR112019004314A BR112019004314A BR112019004314A2 BR 112019004314 A2 BR112019004314 A2 BR 112019004314A2 BR 112019004314 A BR112019004314 A BR 112019004314A BR 112019004314 A BR112019004314 A BR 112019004314A BR 112019004314 A2 BR112019004314 A2 BR 112019004314A2
Authority
BR
Brazil
Prior art keywords
insulin
variant
amino acid
formula
chain
Prior art date
Application number
BR112019004314A
Other languages
English (en)
Inventor
Anastasiou Alexandra
Gatos Dimitrios
Barlos Kleomenis
Original Assignee
Chemical & Biopharmaceutical Laboratories Of Patras S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemical & Biopharmaceutical Laboratories Of Patras S A filed Critical Chemical & Biopharmaceutical Laboratories Of Patras S A
Publication of BR112019004314A2 publication Critical patent/BR112019004314A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

um primeiro aspecto da invenção refere-se a um composto polipeptídico de fórmula geral (i): a-c-b (i) em que: a é a cadeia a da insulina ou um derivado funcional ou uma sua variante; b é a cadeia b da insulina ou um derivado funcional ou uma sua variante; c é um peptídeo com a fórmula: (x1)p - (x2)n - (x3)q em que: cada x1 e x3 representa, independentemente, um aminoácido básico; cada x2 representa, independentemente, um aminoácido natural ou não natural; p é 1 ou 2; q é 0, 1 ou 2: n é 0, 1, 2 ou 3. outros aspectos da invenção referem-se a composições farmacêuticas que compreendem o referido composto polipeptídico e suas utilizações terapêuticas. outro aspecto refere-se à utilização dos referidos compostos polipeptídicos na preparação de insulina e os seus derivados.
BR112019004314A 2016-09-06 2017-09-05 derivados pró-insulina BR112019004314A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR20160100458 2016-09-06
PCT/IB2017/055336 WO2018047062A1 (en) 2016-09-06 2017-09-05 Proinsulin derivatives

Publications (1)

Publication Number Publication Date
BR112019004314A2 true BR112019004314A2 (pt) 2019-05-28

Family

ID=59895344

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019004314A BR112019004314A2 (pt) 2016-09-06 2017-09-05 derivados pró-insulina

Country Status (10)

Country Link
US (1) US11230585B2 (pt)
EP (1) EP3509625A1 (pt)
JP (1) JP2019530473A (pt)
KR (1) KR20190043609A (pt)
CN (1) CN110234339A (pt)
AU (1) AU2017322552B2 (pt)
BR (1) BR112019004314A2 (pt)
CA (1) CA3035850A1 (pt)
IL (1) IL265182A (pt)
WO (1) WO2018047062A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3756679A1 (en) 2019-06-28 2020-12-30 Université de Genève Compositions for use in the treatment of insulin deficiency conditions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
DK129385A (da) 1985-03-22 1986-09-23 Novo Industri As Peptider og fremstilling deraf
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
CN1231259C (zh) * 1994-12-29 2005-12-14 萨文特医药公司 生产人胰岛素
JP4624495B2 (ja) 1994-12-29 2011-02-02 フェリング・インターナショナル・センター・エス．・エー． ヒト・インスリンの生成
CA2223272A1 (en) 1995-05-05 1996-11-07 Ronald Eugene Chance Single chain insulin with high bioactivity
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
HUP0004169A3 (en) 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
GB9812675D0 (en) 1998-06-11 1998-08-12 Univ Edinburgh Peptides
ATE270306T1 (de) 2000-10-02 2004-07-15 Univ Yonsei Seoul Einkettige insulinanaloge
KR100449454B1 (ko) * 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
WO2002079251A2 (en) * 2001-04-02 2002-10-10 Novo Nordisk A/S Method for making human insulin precursors
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
EP1863840A1 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
JP2009527526A (ja) 2006-02-21 2009-07-30 ノボ・ノルデイスク・エー／エス 単鎖インスリンのアナログとその製薬的製剤
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
US10100098B2 (en) * 2006-12-13 2018-10-16 Stelis Biopharma Private Limited Insulin production methods and proinsulin constructs
GR1006941B (el) * 2009-06-01 2010-08-27 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Πεπτιδικη συνθεση (peptide synthesis)
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
GB201321489D0 (en) * 2013-12-05 2014-01-22 Chemical & Biopharmaceutical Lab Of Patras S A Biologically active insulin derivatives
ES2754271T3 (es) * 2013-12-17 2020-04-16 Novo Nordisk As Polipéptidos escindibles por enteroquinasa

Also Published As

Publication number Publication date
CN110234339A (zh) 2019-09-13
AU2017322552B2 (en) 2021-12-02
JP2019530473A (ja) 2019-10-24
US20190263881A1 (en) 2019-08-29
US11230585B2 (en) 2022-01-25
WO2018047062A1 (en) 2018-03-15
KR20190043609A (ko) 2019-04-26
AU2017322552A1 (en) 2019-03-28
EP3509625A1 (en) 2019-07-17
IL265182A (en) 2019-05-30
CA3035850A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
CY1123260T1 (el) Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
PH12020551691A1 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EA202191286A1 (ru) Ингибитор 15-pgdh
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
NO20092774L (no) HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
ME00454B (me) Nova so perindoprila i farmaceutske kompozicije koje sadrže tu so
CL2020000627A1 (es) Nueva combinación de agentes activos para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas (pf-ild).
AR108631A1 (es) Formulación de neurotoxinas
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
HRP20180468T1 (hr) Novi derivat analoga inzulina
UY38068A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
EP4400098A3 (en) Co-amorphous forms of beta-lactoglobulin and a drug substance
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
CO2020011860A2 (es) Compuestos de 4–metildihidropirimidinona y su uso farmacéutico
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
CY1126071T1 (el) Φαρμακευτικα σκευασματα αναλογων κυκλοσπορινης
BR112019004314A2 (pt) derivados pró-insulina
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.
EA202090143A1 (ru) Фармацевтически приемлемые соли полипептидов и их применение
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
BR112017003783A2 (pt) soluto e mistura de soluto assim como uma composição contendo pelo menos um soluto para o uso na prevenção ou tratamento de eflorescências cosméticas ou patológicas causadas por material particulado suspensão

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2791 DE 02-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.